166 related articles for article (PubMed ID: 37410037)
1. Women of Childbearing Age With Hidradenitis Suppurativa Frequently Prescribed Medications With Pregnancy Risk.
Rivin GM; Fleischer AB
J Drugs Dermatol; 2023 Jul; 22(7):706-709. PubMed ID: 37410037
[TBL] [Abstract][Full Text] [Related]
2. Two Cases of Hidradenitis Suppurativa Treated with Adalimumab at the Department of Dermatology and Venereology, Clinical Hospital Mostar.
Lovrić I; Brkić J; Ćorluka M; Čović M; Pejić J; Zeljko Penavić J
Acta Dermatovenerol Croat; 2021 Jul; 29(2):108-110. PubMed ID: 34477078
[TBL] [Abstract][Full Text] [Related]
3. Prescription of teratogenic medications in United States ambulatory practices.
Schwarz EB; Maselli J; Norton M; Gonzales R
Am J Med; 2005 Nov; 118(11):1240-9. PubMed ID: 16271908
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of Hidradenitis Suppurativa Disease Course During Pregnancy and Postpartum.
Lyons AB; Peacock A; McKenzie SA; Jacobsen G; Naik HB; Shi VY; Hamzavi IH; Hsiao JL
JAMA Dermatol; 2020 Jun; 156(6):681-685. PubMed ID: 32347884
[TBL] [Abstract][Full Text] [Related]
5. Pregnancy and breastfeeding in hidradenitis suppurativa: A review of medication safety.
Collier EK; Seivright JR; Shi VY; Hsiao JL
Dermatol Ther; 2021 Jan; 34(1):e14674. PubMed ID: 33320387
[TBL] [Abstract][Full Text] [Related]
6. Outcomes of pregnancy and childbirth in women with hidradenitis suppurativa.
Sakya SM; Hallan DR; Maczuga SA; Kirby JS
J Am Acad Dermatol; 2022 Jan; 86(1):61-67. PubMed ID: 34153386
[TBL] [Abstract][Full Text] [Related]
7. Teratogenic medications and concurrent contraceptive use in women of childbearing ability with epilepsy.
Bhakta J; Bainbridge J; Borgelt L
Epilepsy Behav; 2015 Nov; 52(Pt A):212-7. PubMed ID: 26460786
[TBL] [Abstract][Full Text] [Related]
8. Adalimumab Treatment in Women With Moderate-to-Severe Hidradenitis Suppurativa from the Placebo-Controlled Portion of a Phase 2, Randomized, Double-Blind Study.
Gottlieb A; Menter A; Armstrong A; Ocampo C; Gu Y; Teixeira HD
J Drugs Dermatol; 2016 Oct; 15(10):1192-1196. PubMed ID: 27741335
[TBL] [Abstract][Full Text] [Related]
9. Analysis of Characteristics and Trends in Treatment Response of Hidradenitis Suppurativa Patients: A Southern US Cohort Study.
Peterson GC; Preston A; Frieder J; Wang X; Paek SY
Dermatology; 2020; 236(5):413-420. PubMed ID: 31935718
[TBL] [Abstract][Full Text] [Related]
10. High-Risk Medication Prescriptions in Primary Care for Women Without Documented Contraception.
Panchal BD; Cash R; Moreno C; Vrontos E; Bourne C; Palmer S; Simpson A; Panchal AR
J Am Board Fam Med; 2019; 32(4):474-480. PubMed ID: 31300567
[TBL] [Abstract][Full Text] [Related]
11. Dermatologic Management of Hidradenitis Suppurativa and Impact on Pregnancy and Breastfeeding.
Chellappan B; Nguyen DDQ; Hoyer P; Ross L
Cutis; 2022 Mar; 109(3):160-162. PubMed ID: 35659142
[TBL] [Abstract][Full Text] [Related]
12. The Bacteriology of Skin Lesions in Patients with Hidradenitis Suppurativa Is Associated with Previous Antibiotic Treatment in the Community Setting: A Referral Center Experience.
Barmatz S; Fisch-Gilad S; Hackett A; Barak Levitt J; Dalal A; Taieb Y; Kremer N; Levi A; Pavlovsky L; Hodak E; Yahav D; Sherman S
Dermatology; 2022; 238(4):772-784. PubMed ID: 35086093
[TBL] [Abstract][Full Text] [Related]
13. A Review of the Current Landscape of Hidradenitis Suppurativa Treatment Development.
Westerkam L; Sayed C
J Drugs Dermatol; 2023 Oct; 22(10):1021-1026. PubMed ID: 37801538
[TBL] [Abstract][Full Text] [Related]
14. Underuse of pregnancy testing for women prescribed teratogenic medications in the emergency department.
Goyal MK; Hersh AL; Badolato G; Luan X; Trent M; Zaoutis T; Chamberlain JM
Acad Emerg Med; 2015 Feb; 22(2):192-6. PubMed ID: 25639672
[TBL] [Abstract][Full Text] [Related]
15. Botulinum Toxin in Hidradenitis Suppurativa: A Systematic Review.
Ravi M; Trinidad J
J Drugs Dermatol; 2022 Apr; 21(4):408-412. PubMed ID: 35389587
[TBL] [Abstract][Full Text] [Related]
16. Increased Doses of Adalimumab are Associated With Clinical Improvement of Hidradenitis Suppurativa.
Williams J; Guzik C; Wadhera A; Naik H
J Drugs Dermatol; 2023 Jun; 22(6):615-618. PubMed ID: 37276155
[TBL] [Abstract][Full Text] [Related]
17. HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase 2 adalimumab study.
Kimball AB; Sobell JM; Zouboulis CC; Gu Y; Williams DA; Sundaram M; Teixeira HD; Jemec GB
J Eur Acad Dermatol Venereol; 2016 Jun; 30(6):989-94. PubMed ID: 26201313
[TBL] [Abstract][Full Text] [Related]
18. Evidence-based approach to the treatment of hidradenitis suppurativa/acne inversa, based on the European guidelines for hidradenitis suppurativa.
Gulliver W; Zouboulis CC; Prens E; Jemec GB; Tzellos T
Rev Endocr Metab Disord; 2016 Sep; 17(3):343-351. PubMed ID: 26831295
[TBL] [Abstract][Full Text] [Related]
19. Treatment strategies for hidradenitis suppurativa: real-life data from a tertiary Greek hospital.
Tsentemeidou A; Sotiriou E; Vakirlis E; Sideris N; Lallas A; Ioannides D
Arch Dermatol Res; 2022 Apr; 314(3):301-305. PubMed ID: 33094412
[TBL] [Abstract][Full Text] [Related]
20. An assessment of current practices in the treatment of hidradenitis suppurativa: the rise of biologic therapy.
Muddasani S; Flood KS; Fleischer AB
J Dermatolog Treat; 2022 May; 33(3):1424-1427. PubMed ID: 32940551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
